Clinical Trials

Clinical Trial Detail

Return to search results.

tudy of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Complete title: A randomized, prospective, double blind, placebocontrolled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors

Research Study Number       2523.00
Principal Investigator       Paul Martin, MD
Phase       III

Look up trial at NIH

Research Study Description

The study objective is to compare the efficacy and safety of US-ATG-F as a supplement to standard of care prophylaxis versus standard of care prophylaxis alone in moderate to severe chronic GVHD-free survival.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number       2523.00
Contact       Seattle Cancer Care Alliance Intake Office
Telephone       800-804-8824 / 206-288-1024

Acute Myeloid Leukemia (AML); Hematologic Malignancies; Leukemia; Lymphoproliferative Disease; Myelodysplastic and Myeloproliferative Syndromes (MDS and MPD)

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

Subscribe to an RSS feed of all trials